Pluristem Therapeutics (PSTI) Getting Somewhat Positive Press Coverage, Analysis Shows
Media stories about Pluristem Therapeutics (NASDAQ:PSTI) have trended somewhat positive recently, according to AlphaOne. The research group, a subsidiary of Accern, identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Pluristem Therapeutics earned a media sentiment score of 0.10 on AlphaOne’s scale. AlphaOne also assigned news headlines about the biotechnology company an impact score of 33 out of 100, meaning that recent press coverage is unlikely to have an effect on the company’s share price in the next few days.
Pluristem Therapeutics (NASDAQ:PSTI) traded down 3.40% during trading on Tuesday, hitting $1.42. 297,595 shares of the company were exchanged. Pluristem Therapeutics has a 12 month low of $1.04 and a 12 month high of $1.85. The company’s market capitalization is $136.41 million. The company has a 50-day moving average of $1.27 and a 200-day moving average of $1.38.
Several analysts have recently weighed in on PSTI shares. Maxim Group set a $3.00 price target on shares of Pluristem Therapeutics and gave the company a “buy” rating in a research note on Tuesday, January 17th. FBR & Co reaffirmed a “buy” rating on shares of Pluristem Therapeutics in a research report on Tuesday, January 10th. HC Wainwright set a $4.00 price objective on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a research report on Saturday, February 11th. Finally, Zacks Investment Research raised shares of Pluristem Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a research report on Wednesday, February 15th.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.